Key Takeaways

  • Academic freedom isn't a luxury, it's a speed advantage. Bo Wang argues university labs, free from immediate profit pressures, are the wellspring for radically new concepts, like the biological priors behind Zera Therapeutics' X-Cell model. This deep, unconstrained thinking is hard to replicate in industry.
  • Industry success often builds on academic foundations. Ci Chu points out that while companies like Zera scale data generation (e.g., with Perturb-seq), the core methods and experimental designs frequently originate from university research. Your "industry breakthrough" often has an academic grandparent.
  • Open science accelerates early fields for everyone. For nascent areas like virtual cell modeling, withholding data or models slows progress for the entire domain. Zera’s commitment to sharing, according to Bo Wang, creates a win-win, moving the science forward faster than proprietary hoarding ever could.
  • The relentless pace of AI creates real anxiety. Bo Wang admits to feeling pressure, waking up to new papers that make his own work feel outdated. This intense competition makes collaboration and shared knowledge, not isolation, a survival strategy.

The Unseen Engine Driving Your Next Breakthrough

Founders often default to the "more resources, more speed" mindset. Build a bigger team, buy more GPUs, crank out code. But Bo Wang, a co-founder of Zera Therapeutics, pushes back on that simple equation. For him, the secret engine for biotech AI's rapid pace isn't just silicon and venture capital; it's the quiet, often underfunded, work happening in academia.

“I still deeply believe that academic is the main source of innovation for the whole field and particularly when it comes to biotech,” Wang says. He’s talking about something intangible: academic freedom. This freedom lets researchers chase theories without immediate market demands, leading to truly novel ideas. It’s where models like Zera's X-Cell, which predict cellular responses, get their initial, unconventional spark – often from biological priors that a profit-driven roadmap might sideline.

Ci Chu, another Zera co-founder, agrees. Industry might scale, but it rarely invents the wheel from scratch. “Just thinking about the lab workflow that we do, a lot of these are building upon innovations that were first pioneered in academia as well.” Companies, then, become incredible amplifiers for academic breakthroughs, taking high-throughput methods like Perturb-seq and applying them at an industrial scale that university labs could never manage alone.

Open Science: The Counter-Intuitive Speed Hack

The speed of AI development can feel like a constant race against an invisible clock. “The pace of AI is just so incredibly fast,” Wang says, “to the point that sometimes I feel anxiety waking up says oh my god this paper already so many people published.” This anxiety often pushes companies to lock down their IP, to protect every scrap of data and every model.

Zera, however, takes a different path, especially for virtual cell modeling. Wang explains their commitment to open science, sharing models and data. Why? Because the field is so early. “It doesn't help to withhold certain data sets or certain models because it's so early. A better win-win situation is everybody gets to in this field start to contribute data together, start to contribute models together to exchange ideas so that this field can move forward in a much faster pace.”

This isn't just idealism; it's a pragmatic play. By giving away some of their foundational work, Zera isn't just being "good citizens." They're effectively crowd-sourcing the early-stage R&D, accelerating the entire ecosystem they operate within. When everyone contributes, everyone benefits from a richer, faster-evolving knowledge base. It's a strategic surrender of short-term exclusivity for long-term category growth.

What to Do With This

Stop viewing academia as a separate world or merely a talent pipeline. Identify one foundational, early-stage problem in your biotech AI stack that isn't core IP. Reach out to a university lab working on a similar problem this week, and explore a data-sharing partnership or even an open-source collaboration. Your willingness to contribute, rather than hoard, could become your most potent accelerator.